Rosette-forming glioneuronal tumours are midline, FGFR1-mutated tumours.
Fiche publication
Date publication
mars 2022
Journal
Neuropathology and applied neurobiology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GAUCHOTTE Guillaume, Dr LHERMITTE Benoît
Tous les auteurs :
Appay R, Bielle F, Sievers P, Barets D, Fina F, Boutonnat J, Clovis A, Gauchotte G, Godfraind C, Lhermitte B, Maurage CA, Meyronet D, Mokhtari K, Rousseau A, Tauziède-Espariat A, Tortel MC, Uro-Coste E, Burel-Vandenbos F, Chotard G, Pesce F, Varlet P, Colin C, Figarella-Branger D
Lien Pubmed
Résumé
Rosette-forming glioneuronal tumour (RGNT) is a rare CNS WHO grade 1 brain neoplasm. According to WHO 2021, essential diagnostic criteria are a "biphasic histomorphology with neurocytic and a glial component, and uniform neurocytes forming rosettes and/or perivascular pseudorosettes associated with synaptophysin expression" and/or DNA methylation profile of RGNT whereas "FGFR1 mutation with co-occurring PIK3CA and/or NF1 mutation" are desirable criteria.
Mots clés
2021 WHO classification of CNS tumours, DNA methylation profiling, FGFR1, PIK3CA, PIK3R1, RGNT, multiplexed digital PCR
Référence
Neuropathol Appl Neurobiol. 2022 Mar 16;:e12813